The estimated Net Worth of Capital Group Ii Llc Hopkins is at least $20.7 Milion dollars as of 5 September 2007. Capital Hopkins owns over 15,459 units of Biodelivery Sciences International stock worth over $20,663,564 and over the last 17 years Capital sold BDSI stock worth over $77,295.
Capital has made over 1 trades of the Biodelivery Sciences International stock since 2007, according to the Form 4 filled with the SEC. Most recently Capital sold 15,459 units of BDSI stock worth $77,295 on 5 September 2007.
The largest trade Capital's ever made was selling 15,459 units of Biodelivery Sciences International stock on 5 September 2007 worth over $77,295. On average, Capital trades about 5,153 units every 0 days since 2007. As of 5 September 2007 Capital still owns at least 3,696,523 units of Biodelivery Sciences International stock.
You can see the complete history of Capital Hopkins stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is 709 THE HAMPTONS LN., , TOWN AND COUNTRY, MO, 63017.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott a Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: